Exchange Traded Concepts LLC Has $179,000 Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Exchange Traded Concepts LLC lifted its stake in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 244.7% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 89,076 shares of the company’s stock after buying an additional 63,235 shares during the period. Exchange Traded Concepts LLC’s holdings in RAPT Therapeutics were worth $179,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Acadian Asset Management LLC acquired a new stake in RAPT Therapeutics in the first quarter worth $97,000. EntryPoint Capital LLC acquired a new stake in shares of RAPT Therapeutics in the 1st quarter valued at about $161,000. Denali Advisors LLC acquired a new stake in shares of RAPT Therapeutics in the 1st quarter valued at about $293,000. XTX Topco Ltd bought a new stake in RAPT Therapeutics in the 2nd quarter valued at about $108,000. Finally, Hennion & Walsh Asset Management Inc. raised its stake in RAPT Therapeutics by 8.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock worth $148,000 after buying an additional 3,824 shares during the period. Institutional investors own 99.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on RAPT. UBS Group reduced their price objective on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating for the company in a research note on Monday, September 9th. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a research report on Tuesday, August 20th. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $18.17.

RAPT Therapeutics Stock Down 8.1 %

RAPT stock opened at $1.65 on Tuesday. The stock’s 50 day moving average is $2.00 and its 200-day moving average is $3.75. RAPT Therapeutics, Inc. has a twelve month low of $1.64 and a twelve month high of $27.35. The firm has a market capitalization of $57.42 million, a PE ratio of -0.54 and a beta of 0.33.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.03. On average, equities research analysts anticipate that RAPT Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.